Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Wave Life Sciences Ltd.NASDAQ: WVE

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $26.09M (cash outflow) fell 44.4% year over year, behind the +63.4% change in trailing-twelve-month net income. Sequentially, it fell 50.9% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Net income amounted to 478.3% of revenue in FY2025, up 388.8 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 15 analysts of -$173.72M (-15.0%) for the fiscal year ending Dec 2026, a slowdown from the +110.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.09M-50.9% QoQ
Last fiscal yearDec 2025
-$204.38M+110.7% YoY
LTMMar 2026
-$183.59M+63.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.4%+21.3%+65.6 pp
1 year+110.7%-15.0%-125.7 pp
3-year CAGR+8.1%+12.8%+4.7 pp
5-year CAGR-23.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(204.38M) USD
Year-over-year change
-110.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +63.4% is the 4th highest of 10, against a peer median of +51.2%.
  • Net income amounts to 255.7% of revenue for WVE, versus a peer median of 173.5%.
WVE Competitors
Net Income for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$807.99M USD+353.2%—16.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$717.13M USD-2481.4%+50.8%159.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M USD-4.8%+3.1%757.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$183.59M USD+63.4%+8.1%255.7%
STOKStoke Therapeutics, Inc.LTM Mar 2026$169.77M USD-437.7%-59.2%529.2%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.06M USD+126.2%+0.5%3.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026$41.54M USD+56.8%+27.7%—
Peer median (excluding WVE) —+51.2%+7.6%173.5%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
Deferred Income Tax(12.64M)0000
Stock-Based Compensation16.41M17.19M9.8M13.14M0
Change in Working Capital7.01M6.72M19.08M(75.82M)(16.94M)
Accounts Receivables30M0(21.09M)19.66M146K
Inventory2.04M0000
Accounts Payables(6.57M)9.35M(3.76M)3.42M(561K)
Other Working Capital(18.46M)(2.63M)43.93M(98.91M)(16.53M)
Other Non-Cash Items12.64M12K0024.97M
Operating Cash Flow(88.99M)(127.78M)(19.43M)(151.03M)(187.49M)
Capital Expenditures(560K)(1.36M)(1.12M)(938K)(718K)
Acquisitions (Net)00000
Purchases of Investments0(75.04M)000
Sales of Investments075.04M000
Other Investing Activities0106K000
Investing Cash Flow(560K)(1.26M)(1.12M)(938K)(718K)
Debt Repayment00000
Common Stock Issued54.97M52.33M131.28M236.18M488.24M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities858K14.86M1.26M17.71M0
Financing Cash Flow55.83M67.19M132.53M253.89M488.24M
Effect of Forex Changes(208K)(210K)(95K)(138K)12K
Net Change in Cash(33.93M)(62.06M)111.89M101.79M300.04M
Free Cash Flow(89.55M)(129.14M)(20.55M)(151.96M)(187.49M)

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.